Exelixis received a rating upgrade following an upward trend in earnings estimates, which institutional investors use for valuation.
2 reports, 1 independent
Updated Jul 30
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Exelixis received a rating upgrade following an upward trend in earnings estimates, which institutional investors use for valuation.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Exelixis
American biotechnology company
Nothing else this week.
Coverage
Newest first; wire copies grouped- ZacksAll You Need to Know About Exelixis (EXEL) Rating Upgrade to Strong Buy Investors might want to bet on Exelixis (EXEL), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating c
- ZacksExelixis (EXEL) Beats Q2 Earnings Estimates Exelixis (EXEL) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.65 per share. This compares to earnings of